GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE).
Biotechnology Company Announces Preclinical Data: Type 2 NKT Activating Molecules
Biotechnology Company Announces Preclinical…
Biotechnology Company Announces Preclinical Data: Type 2 NKT Activating Molecules
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE).